These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 14627400)

  • 1. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
    Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
    Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM; Barnes MC; Dowle MD; Hind SL; Johnson MR; Jones PS; Mills G; Patikis A; Pateman TJ; Redfern TJ; Robinson JE; Slater MJ; Trivedi N
    Org Lett; 2003 Nov; 5(24):4631-4. PubMed ID: 14627401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents.
    Andrews DM; Chaignot H; Coomber BA; Good AC; Hind SL; Johnson MR; Jones PS; Mills G; Robinson JE; Skarzynski T; Slater MJ; Somers DO
    Org Lett; 2002 Dec; 4(25):4479-82. PubMed ID: 12465917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
    Perni RB; Chandorkar G; Cottrell KM; Gates CA; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao G; Schairer WC; Van Drie J; Wei Y
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3406-11. PubMed ID: 17482818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
    Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
    Duan M; Kazmierski W; Crosby R; Gartland M; Ji J; Tallant M; Wang A; Hamatake R; Wright L; Wu M; Zhang YK; Ding CZ; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2993-6. PubMed ID: 22425454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.